Amphion Innovations plc

Amphion Partner Company, Polarean Imaging Limited,
Closes Interim Funding

London and New York, 22 December 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces a further update regarding its partner company Polarean Imaging Limited (“Polarean”), in which Amphion currently has an interest of circa 26%.

Further to the Company’s announcement of 22 November 2017, Polarean has successfully closed on £647,127.00 in interim funding in the form of a Convertible Promissory Note (CPN). The CPN will automatically convert into fully paid Ordinary Shares of Polarean at a conversion price equal to 90% of the Issue Price of Ordinary Shares upon Admission to trading of the Ordinary Shares to the AIM market of the London Stock Exchange. In the event the Ordinary Shares are not admitted to trading by 31 March 2018, the CPN will be repayable over 10 months from 1 April. The proceeds will be used to ensure there are adequate financial resources to complete the proposed IPO which is expected in Q1 2018, market conditions permitting.

Further announcements will be made by both Amphion and Polarean in due course.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Certain capitalised terms in this announcement are with reference to the announcement made by Amphion at 7.00 a.m. (GMT) on 10 November 2017.

---

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Mike Wort / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.